{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:18:25Z","timestamp":1759936705527},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.transci.2010.01.011","type":"journal-article","created":{"date-parts":[[2010,1,28]],"date-time":"2010-01-28T11:14:01Z","timestamp":1264677241000},"page":"151-156","source":"Crossref","is-referenced-by-count":1,"title":["Controversies in the management of fever in the neutropenic cancer patient"],"prefix":"10.1016","volume":"42","author":[{"given":"Matthew D.","family":"Seftel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2010.01.011_bib1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"Guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2010.01.011_bib2","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1086\/588290","article-title":"The influence of mucositis on oral thermometry: when fever may not reflect infection","volume":"46","author":"Ciuraru","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2010.01.011_bib3","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2010.01.011_bib4","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1182\/blood.V106.11.2668.2668","article-title":"Mortality during treatment of patients with advanced Hodgkin\u2019s lymphoma undergoing dose escalated BEACOPP chemotherapy: an analysis of the german Hodgkin study group (GHSG). ASH Annual Meeting Abstracts","volume":"106","author":"Fuchs","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.transci.2010.01.011_bib5","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/cncr.11827","article-title":"Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma","volume":"98","author":"Lyman","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.transci.2010.01.011_bib6","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.transci.2010.01.011_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/10428190701809172","article-title":"Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences","volume":"49","author":"Hamalainen","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transci.2010.01.011_bib8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V112.11.666.666","article-title":"Serum lactic acid (LA) as a predictor of septic shock in patients with hematologic malignancies (HM) who develop febrile neutropenia. ASH Annual Meeting Abstracts","volume":"112","author":"Mato","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.transci.2010.01.011_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00520-006-0185-8","article-title":"Institut Jules Bordet, Centre des Tumeurs de l\u2019Universite Libre de Bruxelles. Risk-adapted strategy for the management of febrile neutropenia in cancer patients","volume":"15","author":"Klastersky","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.transci.2010.01.011_bib10","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2010.01.011_bib11","unstructured":"Qx MD Hematology. Available from: <http:\/\/www.qxmd.com\/hematology\/MASCC-Febrile-Neutropenia-Risk.php> (accessed 27.02.09)."},{"key":"10.1016\/j.transci.2010.01.011_bib12","first-page":"424","article-title":"The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988\u20132004","volume":"9","author":"Paul","year":"2007","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.transci.2010.01.011_bib13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1056\/NEJM199907293410502","volume":"341","author":"Kern","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2010.01.011_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJM199907293410501","article-title":"A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy","volume":"341","author":"Freifeld","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2010.01.011_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.bjc.6600993","article-title":"Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study","volume":"89","author":"Innes","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.transci.2010.01.011_bib16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00520-007-0383-z","article-title":"Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge","volume":"16","author":"Sebban","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.transci.2010.01.011_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/dkh303","article-title":"Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials","volume":"54","author":"Vidal","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.transci.2010.01.011_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/jac\/dki448","article-title":"Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials","volume":"57","author":"Paul","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.transci.2010.01.011_bib19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: a systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.transci.2010.01.011_bib20","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Early communication about an ongoing safety review. Cefepime (marketed as Maxipime). Available from: <http:\/\/www.fda.gov\/Cder\/Drug\/early_comm\/cefepime.htm> (accessed 27.02.09)."},{"key":"10.1016\/j.transci.2010.01.011_bib21","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1086\/597264","article-title":"Cefepime Therapy and All-Cause Mortality","volume":"48","author":"Nguyen","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2010.01.011_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1086\/505393","article-title":"A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies","volume":"43","author":"Bow","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2010.01.011_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.bmt.1705256","article-title":"Piperacillin\/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial","volume":"37","author":"Harter","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2010.01.011_bib24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/clinids\/14.6.1201","article-title":"Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors","volume":"14","author":"Elting","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2010.01.011_bib25","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bmj.326.7399.1111","article-title":"Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis","volume":"326","author":"Paul","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.transci.2010.01.011_bib26","doi-asserted-by":"crossref","unstructured":"Paul M, Borok S, Fraser A, Vidal L, Cohen M, Leibovici L. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 2005;(3):CD003914.","DOI":"10.1002\/14651858.CD003914.pub2"},{"key":"10.1016\/j.transci.2010.01.011_bib27","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1086\/340402","article-title":"Infections caused by viridans streptococci in patients with neutropenia","volume":"34","author":"Tunkel","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2010.01.011_bib28","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/cncr.22205","article-title":"Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions","volume":"107","author":"Leibovici","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.transci.2010.01.011_bib29","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2010.01.011_bib30","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJMoa050078","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas","volume":"353","author":"Cullen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2010.01.011_bib31","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1200\/JCO.2006.08.7395","article-title":"Rational selection of patients for antibacterial prophylaxis after chemotherapy","volume":"25","author":"Cullen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2010.01.011_bib32","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2010.01.011_bib33","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2010.01.011_bib34","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1200\/JCO.2004.00.7955","article-title":"Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study","volume":"23","author":"Timmer-Bonte","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2010.01.011_bib35","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2005.04.3281","article-title":"Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer","volume":"24","author":"Timmer-Bonte","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2010.01.011_bib36","doi-asserted-by":"crossref","unstructured":"Herbst C, Naumann F, Kruse EB, et al. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 2009;(1):CD007107.","DOI":"10.1002\/14651858.CD007107.pub2"},{"key":"10.1016\/j.transci.2010.01.011_bib37","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood.V112.11.1315.1315","article-title":"Preventing infections in cancer patients: antibiotics, hematopoietic growth factors or both? A network analysis. ASH Annual Meeting Abstracts","volume":"112","author":"Herbst","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.transci.2010.01.011_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dkl425","article-title":"Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis","volume":"59","author":"Gafter-Gvili","year":"2007","journal-title":"J Antimicrob Chemother"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050210000121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050210000121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T03:20:37Z","timestamp":1590549637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050210000121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S1473050210000121"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2010.01.011","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}